La cadena de opciones muestra datos clave de las opciones de acciones de Context Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Context Therapeutics..

Context Therapeutics (NASDAQ:CNTX) Bolsa, Cadena de Opciones

Context Therapeutics

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Context Therapeutics Inc

Baker Hughes Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) disclosed several transactions and partnerships at the Baker Hughes <a target="_blank" href="https://www.benzinga.com/quote/BKR" rel="noreferrer noopener">2025 Annual Meeting in Florence</a>.
ExxonMobil Contract: Baker Hughes secured a contract from Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) Guyana to supply specialty chemicals and services for the Uaru and Whiptail offshore <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43426683/baker-hughes-secures-major-chemicals-award-from-exxonmobil-guyana-for-fpsos" rel="noreferrer noopener">developments in the Stabroek Block</a>.
Uaru and Whiptail are ExxonMobil Guyana&#8217;s fifth and sixth projects, featuring up to 20 drill centers and 92 wells.
Each FPSO will have a capacity of 250,000 barrels per day, raising the country's total production capacity to 1.3 million barrels per day.
The multi-year contract covers topsides, subsea, water injection, and utility chemicals for the Errea Wittu and Jaguar FPSOs, set to begin production in 2026 and 2027, respectively.
Hanwha Partnership: Baker Hughes inked a joint Development and Collaboration Agreement (JDCA) with Hanwha Power Systems and Hanwha Ocean to develop a small-size <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43426721/baker-hughes-and-hanwha-announce-partnership-to-develop-small-size-ammonia-turbines" rel="noreferrer noopener">turbine for ammonia applications</a>.
The turbine will combine Baker Hughes&#8217; gas turbine technology with Hanwha&#8217;s ammonia combustion system.
Baker and Hanwha plan to complete full engine testing with ammonia by the end of 2027, after which the ~16MW turbine will be available for commercial orders.
Argent LNG Contract: The company has been chosen by Argent LNG as the liquefaction solution and services provider for its proposed LNG <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43427007/argent-lng-selects-baker-hughes-as-technology-provider-strengthening-project" rel="noreferrer noopener">export facility in Port Fourchon, Louisiana</a>.
Baker Hughes will supply liquefaction technology, power generation equipment, and gas compression systems for the facility, which aims to produce approximately 24 MTPA of LNG.
Last month, Baker Hughes reported fourth-quarter adjusted EPS&nbsp;of $0.70, beating the consensus of $0.63 and sales&nbsp;of $7.36 billion, exceeding <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43356061/baker-hughes-announces-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">the street view of&nbsp;$7.08 billion</a>.
Investors can gain exposure to the stock via iShares U.S. Oil Equipment &amp; Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEZ#NYSE">IEZ</a>) and&nbsp;VanEck Oil Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIH#NYSE">OIH</a>).
Price Action: BKR shares are up 0.39% at $46.36 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43427872" target="_blank" rel="noreferrer noopener">Dow Dips Over 300 Points As Trump Imposes Tariffs On Canada, Mexico, And China: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

News

Contracts

Baker Hughes Lands ExxonMobil Guyana Deal, Partners With Hanwha On Ammonia Turbines

Keybanc analyst Bradley Thomas maintains Tempur Sealy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>) with a Overweight and raises the price target from $66 to $70.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on Tempur Sealy Intl, Raises Price Target to $70

Keybanc analyst Paul Knight maintains Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) with a Overweight and raises the price target from $132 to $145.

RVTY

Keybanc Maintains Overweight on Revvity, Raises Price Target to $145

Keybanc analyst Steve Barger maintains RBC Bearings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) with a Overweight and raises the price target from $375 to $395.

Keybanc Maintains Overweight on RBC Bearings, Raises Price Target to $395

Unusual Machines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) has announced the signing of a binding agreement to acquire of Aloft Technologies, Inc. (<a href="https://pr.report/6pai">https://www.aloft.ai/</a>), the leading FAA-approved provider of unmanned aerial system (UAS) services to enterprise, public safety, and government customers. The acquisition is almost all in stock, valued at $14.5M.
The proposed acquisition brings together companies that share commitment to strengthening the U.S. drone industry. Aloft Technologies has long been recognized as the leader in the drone fleet and airspace management sector, powering more than 70% of all FAA-approved Low Altitude Authorization and Notification Capability (LAANC) airspace authorizations in the United States. Aloft has provided more than more than 1.6 million authorizations in total, with 400,000 authorizations provided in 2024.
Aloft has been able to leverage the data collected through millions of safe flights and airspace interactions to launch <a href="https://pr.report/6paj">Air Boss</a>, their new real-time UAS air traffic management (UTM) software. With the FAA <a href="https://pr.report/6pak">forecasting</a> more than 3 million drones in the airspace by 2028, outnumbering traditional aircraft more than 10-to-1, the coordination and integration of all aircraft is critical to national security and the national economy.
The closing of the acquisition is contingent on satisfaction of customary closing conditions by the parties including Aloft obtaining stockholder approval, the delivery by Aloft of its audited financials acceptable to Unusual Machines, the receipt of certain third party consents and the holders of no more than 10% of Aloft common stock have asserted appraisal rights.

UMAC

Unusual Machines Enters Into Definite Agreement To Acquire Drone Software Company Aloft Technologies; The Acquisition Is Almost All In Stock, Valued At $14.5M

Keybanc analyst Aleksey Yefremov maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Overweight and lowers the price target from $50 to $40.

Keybanc Maintains Overweight on Olin, Lowers Price Target to $40

Buybacks

Axis Capital Enters $200M Stock Repurchase Agreement

LICY

LI-Cycle Further Expands Commercial Footprint In EU With Additional Exclusive Recycling Partnership For Its Germany Spoke

Keybanc analyst Tim Rezvan maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Overweight and lowers the price target from $50 to $37.

Keybanc Maintains Overweight on Murphy Oil, Lowers Price Target to $37

Macro Economic Events

Global

Economics

OPEC+ Discussing Changing List Of Secondary Sources It Uses To Monitor Members' Oil Output; OPEC+ Considers Proposal To Remove U.S. Government's EIA As One Of Its Secondary Sources, Sources Say

Barclays analyst Ramsey El-Assal maintains Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) with a Overweight and raises the price target from $23 to $28.

RELY

Barclays Maintains Overweight on Remitly Global, Raises Price Target to $28

Keybanc analyst Aleksey Yefremov maintains Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) with a Overweight and raises the price target from $121 to $128.

Keybanc Maintains Overweight on Eastman Chemical, Raises Price Target to $128

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) has no revenues. He added, &#8220;It's obviously just a very big spec. I <a href="https://www.benzinga.com/quote/SMMT">can't go there.&#8221;</a>
However, HC Wainwright &amp; Co. analyst Mitchell Kapoor, on Jan. 21, reiterated Summit Therapeutics with a Buy and maintained a $44 price target.
<h3 class="wp-block-heading">This Financial Company Is &#8216;Good&#8217;</h3>
Cramer said HSBC Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSBC#NYSE">HSBC</a>) is a &#8220;good&#8221; company, but added that he would recommend Banco Santander, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) if he is going to buy one of those that's a foreign bank.
HSBC, meanwhile, on Jan.6, named Lisa McGeough as President and CEO for the United States.
<h3 class="wp-block-heading">Tech Stocks In Focus</h3>
When asked about Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>), he said, &#8220;I have read so many upgrades of Western Digital that I have to believe the stock is way too cheap.&#8221;
On the earnings front, Western Digital, on Jan. 29, reported better-than-expected second-quarter revenue results.
AppFolio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) is a &#8220;cheap&#8221; stock, and it's a &#8220;good one,&#8221; Cramer said. &#8220;That one rocks.&#8221;
AppFolio, on Jan. 30, also reported better-than-expected sales results for its fourth quarter.
The Mad Money host said he doesn't want to sell Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) down here. He added, &#8220;I know that it seems like a tough stock to own. I can't sell at 21 times earnings.&#8221;
However, Deutsche Bank analyst Brad Zelnick, on Jan. 8, downgraded Adobe from Buy to Hold and lowered the price target from $600 to $475.
Price Action:
<ul>
<li>HSBC shares fell 0.5% to settle at $52.43 on Friday.</li>
<li>Summit Therapeutics shares fell 3.9% to close at $21.50 during the session.</li>
<li>Western Digital shares fell 1% to settle at $65.13.</li>
<li>AppFolio shares dipped 7.8% to close at $233.91 on Friday.</li>
<li>Adobe shares fell 1.9% to settle at $437.45.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43390127/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Markets

Media

Trading Ideas

ADBE

APPF

HSBC

SMMT

Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There'

Mangoceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRX#NASDAQ">MGRX</a>), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedicine platform, is pleased to announce that it has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc., the developer of skincare brand Dermytol&#xAE;, a clinically proven treatment designed to improve skin tone and reduce hyperpigmentation.
Dermytol&#xAE; is an advanced, plant-based formula developed to address dark spots, uneven skin tone, acne scars, and other pigmentation concerns. Unlike traditional skin treatments that may cause irritation or long-term damage, Dermytol&#xAE; utilizes a proprietary blend of clinically validated ingredients, including canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera. The <a href="https://www.globenewswire.com/Tracker?data=GwtS7MM7faaVuXF50nCiIEqF3YZclunD-W2Oc5djnaJ-5RrV_FkWU1wk8H1HdLecpsBP6LAO4Ulu2toHmYIv0l4gUDm7ZuZbxGlieKMERNfAelXeLjdK926Iw9wNYVLcLx-cgONQPCRwcPM6sjmR-gbN1e2BzjJoBQr-BEkuBWs=">patented</a> formulation harnesses the melanin-reducing properties of canola extract, providing a safer and more stable alternative to conventional ingredients like hydroquinone and kojic acid.
The efficacy of Dermytol&#xAE; as a safe and effective skincare treatment was demonstrated in vitro, where it was tested against Kojic acid—a widely used skin lightening agent derived from fungi. At medium and high concentrations, Dermytol&#xAE; was found to be more effective at reducing melanin production while being significantly less damaging to skin cells than Kojic acid. According to the <a href="https://www.globenewswire.com/Tracker?data=jb3n_m190i60gacTYqoi8qpzZ5EC-ZzRvxQAiOQ2tZabOxrf6vfaMD71kOJmf6Hi6uCZVofXr0q9dN4KnlYDwghRMo-7SZB81FrhmRg1Tm0=">study</a>, this would make Dermytol&#xAE; a superior option for individuals seeking a clinically backed solution for hyperpigmentation and overall skin health.

Biotech

General

MGRX

Mangoceuticals Announces Exclusive Distribution Agreement With Propre Energie For Dermytol, Plant-Based Skincare Proven To Address Hyperpigmentation And Acne Scars

RSLS

ReShape Lifesciences Granted International Patent For Diabetes Neuromodulation Technology In Israel; Protection Until 2039, Terms Not Disclosed

Edible Garden AG Incorporated ("Edible Garden" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>, EDBLW)), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced the expansion of its existing partnership with Walmart. The Company is adding value size fresh-cut basil to its product assortment at Walmart locations. This strategic addition underscores Edible Garden's ongoing commitment to sustainable farming practices and its dedication to reducing environmental impact through Walmart's Project Gigaton.

EDBL

Edible Garden Announces The Expansion Of Its Existing Partnership With Walmart, Adding Value Size Fresh-Cut Basil To Its Product Assortment At Walmart Locations

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) will be reporting its fourth-quarter earnings on Monday. Wall Street expects 11 cents in EPS and $775.91 million in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=PLTR" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 393.36%% over the past year, 9.71% YTD.
Let&#8217;s look at what the charts indicate for Palantir stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com//node/43426284">Palantir Technologies Plunges Overnight On Robinhood: Trump Tariff Impact Or Investor Jitters?</a>
<h2 class="wp-block-heading">PLTR Stock Strongly Bullish Ahead Of Q4 Earnings&#8230;</h2>
PLTR stock is in a strongly bullish trend, trading above its five-day, 20-day and 50-day exponential moving averages. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="626" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03065308/Screenshot-2025-02-03-at-5.22.51-PM.png" alt="" class="wp-image-762426" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03065308/Screenshot-2025-02-03-at-5.22.51-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/03065308/Screenshot-2025-02-03-at-5.22.51-PM-300x235.png 300w" sizes="(max-width: 626px) 100vw, 626px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
At $81.20, the stock sits comfortably above key moving averages, reinforcing upward momentum. Notably, PLTR is well above its eight-day SMA (simple moving average) of $79.79, 20-day SMA of $74.48 and 50-day SMA of $73.06, all bullish indicators suggesting continued strength. 
The 200-day SMA at $42.02 further underscores a long-term uptrend, with the stock having nearly doubled over this period.
Momentum indicators also support the bullish case. The MACD (moving average convergence/divergence) indicator at 2.61 signals increasing upside momentum, often a precursor to further gains. However, the RSI (relative strength index) at 61.03 indicates that while the stock isn&#8217;t yet overbought, it is approaching elevated levels, suggesting some caution as PLTR stock nears resistance zones. 
PLTR stock investors should watch for potential consolidation or minor pullbacks, but the overall technical picture remains bullish.
<h2 class="wp-block-heading">&#8230;Yet Palantir Analysts See 9% Downside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/PLTR/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Palantir stock stands at a Neutral currently with a price target of $39.38. Recent analyst ratings from Wedbush, Cantor Fitzgerald and Morgan Stanley imply an 8.77% downside for PLTR stock, with an average price target of $74.
PLTR Stock Price Action: Palantir stock closed the trading day Friday at $82.49, up 1.56%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com//node/43420511">Palantir CEO Alex Karp Sounds Alarm on China&#8217;s Deepseek – Could This Threaten Palantir&#8217;s AI Dominance?</a></li>
</ul>
Photo: Shutterstock

PLTR

Palantir Q4 Earnings Countdown: Bullish Charts Vs. Bearish Analysts

Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) released its Q4 earnings on Monday, February 3, 2025 at 07:30 AM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Saia beat estimated earnings by 3.0%, reporting an EPS of $2.84 versus an estimate of $2.77.
Revenue was up $37.82 million from the same period last year.
<h3>Earnings History Overview</h3>
The company missed on EPS by $0.07 in the previous quarter, leading to a 11.0% increase share price change the next day.
Here's a look at Saia's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.53</td>
<td>4</td>
<td>3.44</td>
<td>3.20</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.46</td>
<td>3.83</td>
<td>3.38</td>
<td>3.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>839.88M</td>
<td>826.55M</td>
<td>770.66M</td>
<td>744.99M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>842.10M</td>
<td>823.24M</td>
<td>754.77M</td>
<td>751.13M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Saia <a href="https://www.benzinga.com/quote/SAIA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

SAIA

Saia: Q4 Earnings Insights

Stran &amp; Company, Inc. ("Stran" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAG#NASDAQ">SWAG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAGW#NASDAQ">SWAGW</a>), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today reported preliminary selected unaudited results for the fourth quarter and full year ended December 31, 2024.
For the fourth quarter of 2024, revenue is expected to be approximately $27 million, reflecting a 17.8% increase compared to approximately $23 million expected to be reported for the fourth quarter of 2023 on a restated basis. For the full year 2024, revenue is projected to reach approximately $83 million, representing a 9.3% increase from $76 million in 2023. The Company expects to report that it had approximately $18 million in cash equivalents and investments and no long-term debt as of December 31, 2024.

Guidance

SWAG

SWAGW

Stran Announces Q4 2024 Revenue Of $27M, Up 17.8% From $23M In Q4 2023; FY24 Revenue Projected At $83M, A 9.3% Increase Over $76M In 2023; $18M In Cash and Investments, No Long-Term Debt As Of December 31, 2024.

TNYA

Tenaya Therapeutics Receives $8M Clinical Grant From California Institute For Regenerative Medicine; Funding will Support RIDGE-1 Clinical Trial Of TN-401 Gene Therapy

Context Therapeutics GAAP EPS of -$0.22

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Context Therapeutics (CNTX – Research Report), retaining the price target of $10.0...

Context Therapeutics: A Promising Investment in Innovative Oncology Therapies with Strong Financial Position

Context Therapeutics, Inc. ( ($CNTX) ) has released its Q3 earnings. Here is a breakdown of the information Context Therapeutics, Inc. presented to...

Context Therapeutics: Strategic Developments and Financial Outlook

D. Boral Capital initiated coverage of Context Therapeutics (CNTX) with a Buy rating and $9 price target Context is a pioneer in developing T-cell ...

Context Therapeutics initiated with a Buy at D. Boral Capital

An update from Context Therapeutics ( ($CNTX) ) is now available. Context Therapeutics Inc. has entered a $75 million sales agreement with Leerink ...

Context Therapeutics Secures Funding for Cancer Therapy Pipeline

Context Therapeutics (CNTX) has received a new Buy rating, initiated by JMP Securities analyst, Silvan Tuerkcan. Silvan Tuerkcan has given his Buy ...

Innovative Growth Potential: Silvan Tuerkcan's Buy Rating on Context Therapeutics

JMP Securities initiated coverage of Context Therapeutics (CNTX) with an Outperform rating and $4 price target Context is a $97.8M market cap clini...

Context Therapeutics initiated with an Outperform at JMP Securities

Context Therapeutics names Andy Pasternak as chair

Context Therapeutics (CNTX) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6, or CLDN6...

Context doses first patient in Phase 1 clinical trial evaluating CTIM-76

The latest announcement is out from Context Therapeutics ( ($CNTX) ). On January 14, 2025, Context Therapeutics announced that the first patient ha...

Context Therapeutics Advances CTIM-76 in Clinical Pipeline

CNTX

Management

Press Releases

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Comments

Context Therapeutics

Context Therapeutics (CNTX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL